HRP20180182T1 - Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa - Google Patents

Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa Download PDF

Info

Publication number
HRP20180182T1
HRP20180182T1 HRP20180182TT HRP20180182T HRP20180182T1 HR P20180182 T1 HRP20180182 T1 HR P20180182T1 HR P20180182T T HRP20180182T T HR P20180182TT HR P20180182 T HRP20180182 T HR P20180182T HR P20180182 T1 HRP20180182 T1 HR P20180182T1
Authority
HR
Croatia
Prior art keywords
etanercept
resin
separation
mixture
properly folded
Prior art date
Application number
HRP20180182TT
Other languages
English (en)
Croatian (hr)
Inventor
Tsutomu Arakawa
Douglas Farrar
Original Assignee
Coherus Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180182(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences, Inc. filed Critical Coherus Biosciences, Inc.
Publication of HRP20180182T1 publication Critical patent/HRP20180182T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HRP20180182TT 2012-09-11 2013-09-10 Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa HRP20180182T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
EP13838016.7A EP2895188B1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Publications (1)

Publication Number Publication Date
HRP20180182T1 true HRP20180182T1 (hr) 2018-04-20

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180182TT HRP20180182T1 (hr) 2012-09-11 2013-09-10 Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa

Country Status (33)

Country Link
US (6) US20140072560A1 (https=)
EP (1) EP2895188B1 (https=)
JP (3) JP2015533797A (https=)
KR (2) KR102133699B1 (https=)
CN (2) CN110051823A (https=)
AR (1) AR092532A1 (https=)
AU (2) AU2013315750B9 (https=)
BR (1) BR112015005161A2 (https=)
CA (1) CA2882551A1 (https=)
CL (1) CL2015000572A1 (https=)
CO (1) CO7400876A2 (https=)
CY (1) CY1120062T1 (https=)
DK (1) DK2895188T3 (https=)
DO (1) DOP2015000055A (https=)
EA (1) EA031324B1 (https=)
EC (1) ECSP15014138A (https=)
ES (1) ES2657377T3 (https=)
HR (1) HRP20180182T1 (https=)
HU (1) HUE036524T2 (https=)
IL (2) IL237311B (https=)
IN (1) IN2015KN00452A (https=)
LT (1) LT2895188T (https=)
MX (2) MX360044B (https=)
NO (1) NO2972131T3 (https=)
PE (2) PE20150996A1 (https=)
PL (1) PL2895188T3 (https=)
PT (1) PT2895188T (https=)
RS (1) RS57013B1 (https=)
SG (1) SG11201501460RA (https=)
SI (1) SI2895188T1 (https=)
SM (1) SMT201800163T1 (https=)
TW (2) TWI716649B (https=)
WO (1) WO2014043103A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
BR112014009146A8 (pt) 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
SI2895188T1 (en) * 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
MX2016016318A (es) * 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
EP3241849A4 (en) 2014-12-31 2018-06-20 LG Chem, Ltd. Method for producing tnfr-fc fusion protein containing target content of impurities
EP3268042B1 (en) 2015-03-13 2024-11-27 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
JP2018537458A (ja) * 2015-11-18 2018-12-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 改善されたタンパク質分離のための逆ｐＨ塩勾配
BR112018009881A2 (pt) * 2015-11-18 2018-11-13 Merck Patent Gmbh separação de proteína aperfeiçoada em cromatografia de troca iônica
EP4549463A3 (en) * 2016-06-17 2025-07-30 F. Hoffmann-La Roche AG Purification of multispecific antibodies
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018173075A1 (en) * 2017-03-24 2018-09-27 Council Of Scientific And Industrial Research A process for the purification of recombinant antibody fragments
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
WO2022195505A1 (en) * 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法
EP4696709A1 (en) * 2024-12-06 2026-02-18 Qilu Pharmaceutical Co., Ltd. Variants of etanercept and related processes

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
EP1261364A1 (en) 2000-02-10 2002-12-04 Wyeth Method of treating or inhibiting cellular injury or cell death
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
IL157446A0 (en) 2001-02-23 2004-03-28 Immunex Corp Immunex Corp Increased recovery of active proteins
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
JP4980048B2 (ja) 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
BRPI0413197A (pt) 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
KR101150050B1 (ko) * 2004-02-27 2012-07-05 지이 헬스케어 바이오-사이언시스 에이비 항체 정제 방법
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
CA2557046A1 (en) 2004-03-05 2005-10-13 John Crowley Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
CA2638811A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
TW200831129A (en) 2006-10-06 2008-08-01 Amgen Inc Stable formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
NZ595526A (en) 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
BRPI0908270A2 (pt) * 2008-02-29 2019-09-10 Biogen Idec Inc proteínas de fusão de imunoglobulinas purificadas e método para a sua purificação
US9238810B2 (en) * 2008-06-05 2016-01-19 Affibody Ab Polypeptide
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
EP2462157B1 (en) 2009-08-07 2020-06-17 EMD Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
EP2490780A4 (en) * 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
CA2797356C (en) 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
AU2011296702A1 (en) 2010-08-31 2013-03-21 Friesland Brands B.V. Culture medium for eukaryotic cells
EP2627425A4 (en) * 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
EP2699265B1 (en) 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
PT2837680T (pt) 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
KR101454316B1 (ko) * 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
BR112014009146A8 (pt) * 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
SI2895188T1 (en) * 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
EP3879334B1 (en) * 2014-07-31 2023-11-29 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
US20190300602A1 (en) 2019-10-03
US20190330325A1 (en) 2019-10-31
HUE036524T2 (hu) 2018-07-30
KR20150056601A (ko) 2015-05-26
US20190300601A1 (en) 2019-10-03
CY1120062T1 (el) 2018-12-12
CN110051823A (zh) 2019-07-26
EP2895188A4 (en) 2016-05-25
AU2013315750B9 (en) 2018-11-15
JP6913066B2 (ja) 2021-08-04
US10954294B2 (en) 2021-03-23
EA201590542A1 (ru) 2015-07-30
US11001627B2 (en) 2021-05-11
AU2018247244A1 (en) 2018-11-01
JP2019038817A (ja) 2019-03-14
AU2018247244B2 (en) 2020-05-28
PE20150996A1 (es) 2015-08-01
MX2015003090A (es) 2015-07-14
US20140072560A1 (en) 2014-03-13
IL267452B (en) 2021-05-31
JP2021100929A (ja) 2021-07-08
TW201425331A (zh) 2014-07-01
PL2895188T3 (pl) 2018-06-29
TW201803593A (zh) 2018-02-01
ECSP15014138A (es) 2016-01-29
WO2014043103A1 (en) 2014-03-20
CN104902914B (zh) 2019-01-01
US10947306B2 (en) 2021-03-16
SI2895188T1 (en) 2018-05-31
CO7400876A2 (es) 2015-09-30
SMT201800163T1 (it) 2018-05-02
AR092532A1 (es) 2015-04-22
CN104902914A (zh) 2015-09-09
CA2882551A1 (en) 2014-03-20
AU2013315750A1 (en) 2015-03-05
MX2018012749A (es) 2020-11-12
US20190300600A1 (en) 2019-10-03
EP2895188A1 (en) 2015-07-22
EA031324B1 (ru) 2018-12-28
IL237311B (en) 2019-07-31
KR102133699B1 (ko) 2020-07-14
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (https=) 2018-04-21
JP2015533797A (ja) 2015-11-26
US10954295B2 (en) 2021-03-23
RS57013B1 (sr) 2018-05-31
US20180037642A1 (en) 2018-02-08
DK2895188T3 (en) 2018-02-26
IN2015KN00452A (https=) 2015-07-17
IL237311A0 (en) 2015-04-30
US10954293B2 (en) 2021-03-23
SG11201501460RA (en) 2015-04-29
PT2895188T (pt) 2018-02-08
KR20200085937A (ko) 2020-07-15
TWI609877B (zh) 2018-01-01
PE20200607A1 (es) 2020-03-10
EP2895188B1 (en) 2017-11-15
BR112015005161A2 (pt) 2017-07-04
LT2895188T (lt) 2018-04-10
AU2013315750B2 (en) 2018-07-12
ES2657377T3 (es) 2018-03-05
CL2015000572A1 (es) 2016-02-05
IL267452A (en) 2019-08-29
DOP2015000055A (es) 2015-04-30
TWI716649B (zh) 2021-01-21
MX360044B (es) 2018-10-19

Similar Documents

Publication Publication Date Title
HRP20180182T1 (hr) Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
Block et al. Immobilized-metal affinity chromatography (IMAC): a review
KR101569783B1 (ko) 항체의 정제 방법
JP2015042645A5 (https=)
Kinoshita‐Kikuta et al. Enrichment of phosphorylated proteins from cell lysate using a novel phosphate‐affinity chromatography at physiological pH
JP6456376B2 (ja) 組換えタンパク質の精製方法
JP5053089B2 (ja) 化合物の直接単離および多成分サンプルの分別のための磁性材料の使用
ATE462716T1 (de) Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
MX2015005178A (es) Purificacion de polipeptidos usando ultrafiltracion de flujo tangencial de etapa doble.
ATE547521T1 (de) Verfahren zur reinigung von nukleinsäure
IL297116A (en) A method for purifying single-stranded RNA
JP2018516229A5 (https=)
RU2018121657A (ru) ПРОТИВОПОЛОЖНЫЕ ГРАДИЕНТЫ pH-СОЛЬ ДЛЯ УЛУЧШЕННОГО РАЗДЕЛЕНИЯ БЕЛКОВ
RU2018121653A (ru) Улучшенное разделение белков при ионообменной хроматографии
CN102234332A (zh) 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
Jiang et al. A multi-parallel N-glycopeptide enrichment strategy for high-throughput and in-depth mapping of the N-glycoproteome in metastatic human hepatocellular carcinoma cell lines
CN104098697A (zh) 一种重组人源抗人肿瘤坏死因子单克隆抗体的纯化方法
Nascimento et al. Microfluidics as a high-throughput solution for chromatographic process development–the complexity of multimodal chromatography used as a proof of concept
RS60210B1 (sr) Novi postupak za efikasno prečišćavanje humanog albumina iz seruma
Ribeiro et al. Recent stationary phase‐based fractionation strategies in proteomic analysis
KR20170035980A (ko) 항체의 정제 방법
CN107118116A (zh) 一种利用大孔吸附树脂分离纯化5‑氨基戊酸的方法
Yoshimoto et al. Connected flow-through chromatography processes as continuous downstream processing of proteins
WO2011060438A3 (en) Protein separation via ion-exchange chromatography and associated methods, systems and devices
Fröhlich et al. Deep insights into the plant proteome by pretreatment with combinatorial hexapeptide ligand libraries